CD33 and acute myeloid leukemia: While complete tumor eradication remained difficult to achieve, including in animal models [61,64], preclinical results with CD33-specific CAR-T-cells targeting AML cell lines and primary patient samples raised hope for successful clinical translation [65,66,67,68].